secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-08-06T12:20:41+00:00
Accession:  0001493152-26-036268
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce acquires Cy Biopharma, issues Series C Preferred, raises ~$43M in PIPE
------------------------------------------------------------------------------

- Acquired Cy Biopharma on Aug 5, 2026; Cy stockholders received 282,122 shares of Series C Preferred Stock (convertible 1:1,000 into common).
- Raised ~$43M via PIPE: 120,260 Series C shares in two tranches; initial close Aug 7, 2026, milestone tranche subject to clinical trial.
- Lynn Kirkpatrick resigned as President; James Morrison (founder of Cy) appointed President and director, to become CEO after stockholder vote.
- Eliminated Series B Preferred Stock; all outstanding shares converted into 3,229,276 common shares; Certificate of Elimination filed.
- Certain Cy stockholders and company insiders subject to 180-day lock-up on shares received in the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/0001493152-26-036268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226036268/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer